Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Botulinum toxin type A (Botox®) is recommended as an option for use within NHS Wales for the management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis, who are not adequately managed with anticholinergics; patients should be already catheterising or willing and able to catheterise if required. |
|||
|
|||
Medicine details |
|||
| Medicine name | botulinum toxin type A (Botox®) | ||
| Formulation | 50 units powder for solution for injection, 100 units powder for solution for injection, 200 units powder for solution for injection | ||
| Reference number | 1429 | ||
| Indication | Management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis, who are not adequately managed with anticholinergics; patients should be already catheterising or willing and able to catheterise if required |
||
| Company | Allergan Ltd | ||
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 3013 | ||
| NMG meeting date | 23/10/2013 | ||
| AWMSG meeting date | 20/11/2013 | ||
| Ratification by Welsh Government | 06/12/2013 | ||
| Date of issue | 13/12/2013 | ||
| Date of last review | 01/12/2016 | ||